Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy-Reference-Cited by-同舟云学术

Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy

Published:2013-07-30 Issue:4 Volume:21 Page:288-296
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Hafkin J. S.¹²³,Osborn M. K.⁴,Localio A. R.²,Amorosa V. K.¹³,Kostman J. R.¹⁵,Stern J. J.¹⁶,De La Torre P.⁷,Mounzer K.¹⁸,Frank I.¹,Gross R.¹²³,Chang K.-M.³⁹,Lo Re V.¹²³⁵

Affiliation:

1. Division of Infectious Diseases; Department of Medicine, Perelman School of Medicine; University of Pennsylvania; Philadelphia PA USA

2. Department of Biostatistics and Epidemiology; Center for Clinical Epidemiology and Biostatistics; Perelman School of Medicine; University of Pennsylvania; Philadelphia PA USA

3. Medicine Service; Philadelphia Veterans Affairs Medical Center; Philadelphia PA USA

4. Division of Infectious Diseases; Department of Medicine; Emory School of Medicine; Atlanta GA USA

5. Department of Medicine; Penn Presbyterian Medical Center; Philadelphia PA USA

6. Department of Medicine; Pennsylvania Hospital; Philadelphia PA USA

7. Division of Infectious Diseases; Department of Medicine; Cooper University Hospital; Camden NJ USA

8. Jonathan Lax Treatment Center; Philadelphia Field Initiating Group for HIV Trials; Philadelphia PA USA

9. Division of Gastroenterology; Department of Medicine; Perelman School of Medicine; University of Pennsylvania; Philadelphia PA USA

Funder

National Institutes of Health

Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics

Penn Center for AIDS Research

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12142/fullpdf

Reference46 articles.

1. Epidemiology of viral hepatitis and HIV co-infection;Alter;J Hepatol,2006

2. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS);Thio;Lancet,2002

3. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort;Konopnicki;AIDS,2005

5. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection;Antimicrobial Agents and Chemotherapy;2024-09-04

2. Cumulative Tenofovir Exposure Among Patients With Human Immunodeficiency Virus/Hepatitis B Coinfection With Differential Viral Suppression;Clinical Infectious Diseases;2024-05-03

3. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression;AIDS;2023-11-22

4. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study;Journal of Antimicrobial Chemotherapy;2021-08-30

5. Persistent HBV replication and serological response during up to fifteen years of tenofovir-based antiretroviral therapy in HIV-hepatitis B coinfected patients: a multicenter prospective cohort study;2021-07-06